HuMurine Announces Licensing Agreement for hIL6-NOG mice from Taconic Biosciences

LaVerne and Sacramento, California (14th October, 2016): HuMurine Technologies, Inc. (HuMurine) has announced today that it has entered into a licensing agreement with Taconic Biosciences (Taconic) for the commercial use of the hIL6-NOG mouse. The hIL6-NOG mouse expresses human IL-6 cytokine in the NOG mouse background and is useful for the study of tumor infiltrating lymphocytes (TILs) and the modeling of Acute Myeloid Leukemia (AML), Multiple Myeloma (MM) and diseases such as Rheumatoid Arthritis (RA). The humanized hIL6-NOG mouse (Hu-6M™) is now available from HuMurine and has particular relevance in applications in immuno-oncology, autoimmunity and regenerative medicine.